Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
March 30, 2026
Approximately 5 minutes
Local Testing Support for Generic Radiopharmaceuticals During ANDA Registration in China
Overview
A global radiopharmaceutical manufacturer had filed ANDA applications in China for two generic drugs. As part of the registration process, the Chinese regulatory authority required local testing of the drug samples at an official laboratory.
The manufacturer had no local presence in China and needed expert assistance to manage the entire local testing process efficiently and compliantly.
Key Challenges
- Complex sample importation and customs clearance requirements
- Need for analytical method transfer from a US laboratory to the Chinese laboratory
- Coordination of testing activities and timely response to authority queries
- Strict timelines to avoid delays in the overall ANDA approval
Seven-Step Local Testing Solution
-
Preparation and submission of analytical methods to the official Chinese laboratory.
-
Coordination of shipment of samples and reference standards, including confirmation of all import requirements.
-
Management of the analytical method transfer from the US laboratory to the Chinese laboratory.
-
Handling customs clearance and physical shipment of samples to the Chinese laboratory.
-
Responding promptly to all queries raised during the local testing process.
-
Providing continuous technical support to the Chinese laboratory until the official testing report was issued.
-
Managing all communication between the laboratory and the manufacturer to ensure smooth progress.
Results Achieved
- Local testing was completed successfully and on schedule.
- 100% compliance with Chinese regulatory requirements was maintained throughout.
- Standardized procedures delivered high efficiency and consistency.
- The manufacturer was able to rely fully on specialized local expertise for this critical registration step.
This case demonstrates how targeted local testing support enables foreign pharmaceutical companies to meet China’s stringent ANDA requirements for complex radiopharmaceutical generics without establishing a physical presence in the country.
Licensed Pharmacist · Regulatory Affairs Consultant
Pharmacist, RA expert, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
U.S. FDA Office of New Drugs (OND) Organization, Functions, and Key Resources
The FDA’s Office of New Drugs (OND) within CDER reviews new drug and biologic applications, provides regulatory oversight for investigational studies, sets policy for efficient approvals, and maintains key databases such as Drugs@FDA and postmarket requirements, operating through eight review offices with 27 divisions focused on specific therapeutic areas.
Approximately 5 minutes
U.S. FDA Initiatives to Ensure Drug Supply Chain Integrity
The U.S. FDA safeguards the drug supply chain—one of the world’s safest—through the Drug Supply Chain Security Act (DSCSA) for electronic tracing, rapid reporting of illegitimate products, anti-counterfeiting guidance, public education campaigns like BeSafeRx and Know Your Source, and international partnerships to prevent counterfeit, stolen, or harmful drugs from reaching patients.
Approximately 5 minutes
U.S. FDA Drug Development and Approval Process Overview
The U.S. FDA’s Center for Drug Evaluation and Research (CDER) ensures marketed drugs are safe and effective by reviewing sponsor-submitted data in applications such as IND for clinical trials, NDA for new drugs, ANDA for generics, BLA for biologics, and OTC monographs or NDAs for nonprescription products.
Approximately 5 minutes
Harmonized Global Registration of a Class II Hemostatic Valve in Six Key Markets
A US medical device manufacturer successfully registered its Class II hemostatic valve in Australia, Brazil, China, India, Pakistan, and Russia by leveraging existing US, Canadian, and EU approvals and applying a harmonized regulatory strategy with core dossier preparation and efficient project management.